Metabolism
TRIUMPH-4: retatrutide, weight and functional relief in knee osteoarthritis
Before TRIUMPH-1, TRIUMPH-4 already showed a striking profile: high-percentage weight reduction plus reported pain and function improvements.
Source: Eli Lilly — TRIUMPH-4 Phase 3 topline (Dec 2025) (2025) · Original source
In December 2025, Lilly reported positive TRIUMPH-4 topline results for retatrutide in adults with obesity/overweight and knee osteoarthritis, without diabetes.
In the 12 mg arm, the release reported an average 28.7% weight reduction at 68 weeks — about 71.2 lb — with meaningful WOMAC pain subscale improvements.
A responsible reading keeps this inside controlled-trial context. It informs research discussion, not personal self-treatment.
For readers following the science from Asunción, TRIUMPH-4 helps explain why retatrutide drew intense scientific attention.
EDGE VITAL offers RETATRUTIDE+ 60mg in its premium catalog. Check local availability with Eduardo.
Informational research-oriented content. It does not diagnose, prescribe, or replace professional health guidance. EDGE VITAL operates in Asunción with commercial advisory.
Article FAQ
Keep reading
metabolicoRetatrutide: the TRIUMPH-1 results that reshaped metabolic research talk
TRIUMPH-1 topline data placed retatrutide among the most discussed obesity-research findings: a GIP/GLP-1/glucagon triple agonist with high-impact weight outcomes in trial.
Read article
metabolicoKLOW: balance, metabolism and visible vitality
Body composition, metabolic support and wellness — KLOW’s premium positioning.
Read article
metabolicoCBL-514: body composition and advanced research framing
Your best version is in your science — CBL-514’s angle with research focus and premium quality.
Read article